Beovu AU (Brolucizumab PFS) 120mg/mL

Beovu AU (brolucizumab) 120mg/mL is an intravitreal injection for ophthalmic use. It belongs to the VEGF inhibitor class designed to address retinal conditions. Suitable for patients seeking targeted eye therapy options.

Strength

120mg/mL

Manufacturer / TM Owner

Novartis

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Beovu AU (brolucizumab) 120mg/mL is used to treat neovascular (wet) age-related macular degeneration (AMD). It helps reduce abnormal blood vessel growth in the retina. The medication supports vision maintenance by targeting underlying vascular issues. Patients often ask what is brolucizumab used for in eye care.

Side Effects

Beovu AU works by blocking vascular endothelial growth factor (VEGF), a protein that promotes abnormal blood vessel formation. This action helps stabilize retinal layers and may slow vision loss. Some patients notice improved clarity or reduced distortion over time. Effects vary by individual response and treatment stage.

Precautions & Warnings

Store Beovu AU refrigerated between 2°C and 8°C and protect from light. Avoid freezing or shaking the prefilled syringe. Discard any unused portion as directed by healthcare guidelines. Always handle with sterile technique to prevent contamination during administration.

Avoid Interactions

No specific drug interactions have been established for Beovu AU. However, caution is advised when combining with other intravitreal therapies. Patients should inform their doctor about all medications, including supplements. Concurrent use of blood thinners may increase bleeding risk in rare cases.

Frequently Asked Questions

Beovu AU is prescribed for neovascular (wet) age-related macular degeneration to reduce abnormal blood vessel growth in the retina.

Beovu AU is given as an intravitreal injection by a healthcare professional in a clinical setting.

Common effects may include eye redness, pain, or temporary vision changes. Serious reactions are rare but require immediate medical attention.

The safety of Beovu AU in pregnancy has not been established. Consult a healthcare provider for personalized advice.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.